The Medical letter on drugs and therapeutics
-
Hysingla ER, the second single-ingredient extended-release hydrocodone product to become available in the US, is formulated for once-daily use. Zohydro ER is dosed twice daily and costs more. Both Hysingla ER and the new formulation of Zohydro ER have abuse-deterrent properties, but they will still be subject to misuse.
-
Blinatumomab (Blincyto) was effective in inducing a complete remission in 33% of patients with relapsed or refractory Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL). Grade 3 or 4 adverse effects occur frequently.